var data={"title":"Taliglucerase alfa (glucocerebrosidase): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Taliglucerase alfa (glucocerebrosidase): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/506570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Taliglucerase alfa (glucocerebrosidase): Patient drug information&quot;</a> and <a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Taliglucerase alfa (glucocerebrosidase): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14279985\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Elelyso</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28191124\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Elelyso</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14264724\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286854\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Pretreatment with antihistamines and/or corticosteroids can be considered for prevention of subsequent infusion reactions in patients with an infusion reaction requiring symptomatic treatment; during clinical studies, patients were not routinely premedicated prior to infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gaucher disease (type 1):</b> IV: 60 units/kg every 2 weeks; dosing is individualized based on disease severity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conversion from imiglucerase: Initiate taliglucerase alfa using the patient&rsquo;s same previous imiglucerase dose and administer every 2 weeks. <b>Note:</b> Conversion to taliglucerase alfa is based on a single study of patients stabilized on a biweekly imiglucerase dose for &ge;6 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25850974\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Taliglucerase alfa (glucocerebrosidase): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Pretreatment with antihistamines, antipyretics, and/or corticosteroids can be considered for prevention of subsequent infusion reactions in patients with an infusion reaction requiring symptomatic treatment; during clinical studies, patients were not routinely premedicated prior to infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gaucher disease (type 1):</b> Children &ge;4 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286855\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286856\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286857\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14279986\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elelyso: 200 units (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452825\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286828\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Product access is restricted to the Gaucher Personal Support (GPS) program. Healthcare providers and patients may obtain additional information by contacting the GPS program at 855-353-5976.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286858\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IV over a minimum infusion time of 60 minutes (usual infusion time: 60 to 120 minutes). Administer using a low protein-binding infusion set with a 0.2 micron in-line filter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric patients: Initiate infusion at a rate of 1 mL/minute; rate may be increased, but do not exceed 2 mL/minute based on patient tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult patients: Initiate infusion at a rate of 1.2 mL/minute; rate may be increased, but not exceed 2.2 mL/minute based on patient tolerance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14264726\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Gaucher disease: </b> Treatment of adult and pediatric patients with a confirmed diagnosis of type 1 Gaucher disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14287220\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (13% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (children and adolescents: 44%; adults: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (22% to 29%; antibody-positive patients: 35%; patients switching from imiglucerase: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody formation (adults: 13% to 53%; neutralizing but effect on therapeutic response not evaluated: 10%; positive at baseline: 6%; children and adolescents: 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (13%), limb pain (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (4% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to &lt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (9%), fatigue (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (6%), urticaria (6%), skin rash (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (9%), abdominal pain (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Fixed drug eruption (4%; type III immune-mediated; mild and intermittent), anaphylaxis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286832\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Severe hypersensitivity to taliglucerase alfa or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286833\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The development of IgG anti-drug antibodies (ADA) has been reported; the clinical significance is unknown. Patients who develop immune or infusion reactions to taliglucerase alfa or who have had an immune response to other enzyme replacement therapies and who are switching to taliglucerase alfa should be monitored for antibody development; it is unknown if presence of antibodies is related to a higher risk of infusion reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Dizziness and fatigue have been observed with therapy; caution patients about performing dangerous tasks (eg, driving, operating machinery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: Serious hypersensitivity reactions, including anaphylaxis, may occur; these reactions have occurred up to 3 hours after start of infusion. Appropriate medical support should be readily available. Base management of reaction on severity; may include slowing or temporary interruption of infusion and/or premedication (eg, antihistamine, antipyretics, corticosteroids) for mild reactions. Pretreatment may prevent subsequent reactions. Observe patient during and after infusion. If severe reactions occur, immediately discontinue infusion and initiate appropriate treatment; rechallenge with caution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14395111\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14395109\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83880&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286830\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were not observed in animal reproduction studies. Pregnancy may exacerbate existing type I Gaucher disease or result in new symptoms. Women with type I Gaucher disease have an increased risk of spontaneous abortion if disease is not well controlled. Adverse pregnancy outcomes, including hepatosplenomegaly and thrombocytopenia (which may result in increased bleeding and postpartum hemorrhage requiring transfusion), may occur. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17916833\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if taliglucerase alfa is excreted in breast milk. Enzyme ingested by a nursing infant would likely degrade in their digestive system. The benefits of nursing to the infant should be weighed against the potential for additional bone loss in the mother (Zimran, 2009). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286867\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin, platelet count, angiotensin converting enzyme, tartrate-resistant acid phosphatase, chitotriosidase, IgG anti-drug antibody formation (in patients who experience, or previously experienced, immune or infusion reactions to enzyme replacement therapy); liver volume, spleen volume; bone density; ECG, echocardiogram, chest x-ray</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286839\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Taliglucerase alfa is an analogue of glucocerebrosidase; it is produced by recombinant DNA technology using plant (carrot) cell culture. Glucocerebrosidase is an enzyme deficient in Gaucher's disease. It is needed to catalyze the hydrolysis of glucocerebroside to glucose and ceramide, thereby reducing liver and spleen size and improving anemia and thrombocytopenia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14286841\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: Pediatric patients: 8.8 to 14.9 L; Adults: 10.7 to 11.7 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Pediatric patients: 33 to 37 minutes; Adults: 19 to 29 minutes (dose-dependent; increased with higher doses)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322936\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Elelyso Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 unit (1): $935.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25576762\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Eleliso (UA);</li>\n      <li>Elelyso (AU);</li>\n      <li>Uplyso (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Baldellou A, Andria G, Campbell PE, et al, &quot;Paediatric Non-Neuronopathic Gaucher Disease: Recommendations for Treatment and Monitoring,&quot; <i>Eur J Pediatr</i>, 2004, 163(2):67-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-drug-information/abstract-text/14677062/pubmed\" target=\"_blank\" id=\"14677062\">14677062</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charrow J, Andersson HC, Kaplan P, et al, &quot;Enzyme Replacement Therapy and Monitoring for Children With Type 1 Gaucher Disease: Consensus Recommendations,&quot; <i>J Pediatr</i>, 2004, 144(1):112-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-drug-information/abstract-text/14722528/pubmed\" target=\"_blank\" id=\"14722528\">14722528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elelyso (taliglucerase alfa) [prescribing information]. New York, NY: Pfizer Labs; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elelyso (taliglucerase alfa) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jmoudiak M and Futerman AH, &quot;Gaucher Disease: Pathological Mechanisms and Modern Management,&quot; <i>Br J Haematol</i>, 2005, 129(2):178-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-drug-information/abstract-text/15813845/pubmed\" target=\"_blank\" id=\"15813845\">15813845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pastores GM, Weinreb NJ, Aerts H, et al, &quot;Therapeutic Goals in the Treatment of Gaucher Disease,&quot; <i>Semin Hematol</i>, 2004, 41(4 Suppl 5):4-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-drug-information/abstract-text/15468045/pubmed\" target=\"_blank\" id=\"15468045\">15468045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinreb NJ, Aggio MC, Andersson HC, et al, &quot;Gaucher Disease Type 1: Revised Recommendations on Evaluations and Monitoring for Adult Patients,&quot; <i>Semin Hematol</i>, 2004, 41(4 Suppl 5):15-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-drug-information/abstract-text/15468046/pubmed\" target=\"_blank\" id=\"15468046\">15468046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimran A, Brill-Almon E, Chertkoff R, et al, &quot;Pivotal Trial With Plant Cell-Expressed Recombinant Glucocerebrosidase, Taliglucerase Alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease,&quot; <i>Blood</i>, 2011, 118(22):5767-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-drug-information/abstract-text/21900191/pubmed\" target=\"_blank\" id=\"21900191\">21900191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, et al. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. <i>Blood Cells Mol Dis</i>. 2015;54(1):9-16. doi: 10.1016/j.bcmd.2014.10.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-drug-information/abstract-text/25453586/pubmed\" target=\"_blank\" id=\"25453586\">25453586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimran A, Morris E, Mengel E, et al, &ldquo;The Female Gaucher Patient: The Impact of Enzyme Replacement Therapy Around Key Reproductive Events (Menstruation, Pregnancy and Menopause),&rdquo; <i>Blood Cells Mol Dis</i>, 2009, 43(3):264-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/taliglucerase-alfa-glucocerebrosidase-drug-information/abstract-text/19502088/pubmed\" target=\"_blank\" id=\"19502088\">19502088</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83880 Version 57.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14279985\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28191124\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14264724\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14286854\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F25850974\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14286855\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14286856\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14286857\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F14279986\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452825\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F14286828\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14286858\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14264726\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14287220\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14286832\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14286833\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14395111\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14395109\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14286830\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17916833\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14286867\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14286839\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F14286841\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322936\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F25576762\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/83880|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-patient-drug-information\" class=\"drug drug_patient\">Taliglucerase alfa (glucocerebrosidase): Patient drug information</a></li><li><a href=\"topic.htm?path=taliglucerase-alfa-glucocerebrosidase-pediatric-drug-information\" class=\"drug drug_pediatric\">Taliglucerase alfa (glucocerebrosidase): Pediatric drug information</a></li></ul></div></div>","javascript":null}